Expert Perspectives Series – Usher Syndrome and Retinitis Pigmentosa Webcast ProQR Expert Perspectives Series on Usher Syndrome and Retinitis Pigmentosa June 22, 2020
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome Press release … Perspectives Call on Disease Education and Endpoints in Usher Syndrome LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, … February 16, 2021
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome Press release … Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, … March 25, 2020
Expert Perspectives Series - Disease Education and Endpoints in Usher Syndrome Webcast … Perspectives Series - Disease Education and Endpoints in Usher Syndrome ProQR Expert Perspectives Series on Usher Syndrome … February 22, 2021
JMP Securities Grand Rounds KOL Call | PRQR Phase 1/2 Stellar Data in Usher Syndrome Webcast … Grand Rounds KOL Call | PRQR Phase 1/2 Stellar Data in Usher Syndrome Replay link . Biography: Dr. David Birch, Ph.D. Dr. … March 24, 2021
Eye on the Future Forum - Spring Summit Webcast The EFF Spring Virtual Summit hosted by ProQR on April 15 is a virtual meeting featuring the latest clinical data for USH2A mediated Usher syndrome and retinitis pigmentosa and a live panel discussion. April 15, 2021
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. January 02, 2019
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 17, 2021
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates September 05, 2017
ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates July 05, 2017